OPTION-STEMI试验:STEMI合并多支病变患者直接完全血运重建与分期完全血运重建的比较
该多中心、开放标签、非劣效随机试验在韩国14家医院纳入994例STEMI合并多支病变且已对罪犯病变行PCI的患者,1:1随机至直接完全血运重建(同次手术处理非罪犯病变)或分期完全血运重建(本次住院期间另一天处理非罪犯病变)。主要终点为1年全因死亡、非致死性心肌梗死或任何计划外血运重建的复合终点,非劣效界值为HR 1.42。1年主要终点直接组65例(13%) vs 分期组53例(11%),HR 1.24(95%CI 0.86-1.79),非劣效P=0.24,未显示非劣效。卒中、大出血和造影剂肾病发生率两组无显著差异;住院期间心源性休克直接组18/498例(4%) vs 分期组9/496例(2%)。
要点
- STEMI合并多支病变患者直接完全血运重建1年主要终点13% vs 分期11%,HR 1.24(95%CI 0.86-1.79),未达非劣效(非劣效P=0.24)。
- 非劣效界值设定为HR 1.42,单侧97.5%CI上限需低于1.42才判定非劣效,本研究未满足该标准。
- 住院期间心源性休克直接组4%(18/498) vs 分期组2%(9/496)。
- 卒中、大出血、造影剂肾病发生率两组无显著差异。
- 研究结论提示该结果可能为未来指南关于直接完全血运重建的作用和最佳使用提供参考。
适用人群与场景
- 年龄19岁及以上、STEMI合并多支冠状动脉病变、已对罪犯病变行PCI的患者。
- 在韩国14家医院入组,随机分配至直接或分期完全血运重建。
诊断标准与关键阈值
- 非罪犯病变狭窄50-69%者采用血流储备分数评估。
- 非劣效界值:主要终点HR的单侧97.5%CI上限<1.42判定直接完全血运重建非劣于分期完全血运重建。
处置流程与药物剂量
- 直接完全血运重建组:在本次手术中同时对非罪犯病变行PCI。
- 分期完全血运重建组:在本次住院期间另一天对非罪犯病变行PCI。
研究设计与关键结果
- 多中心、开放标签、非劣效随机试验,纳入994例患者,直接组498例、分期组496例。
- 1年主要终点(全因死亡、非致死性心肌梗死或任何计划外血运重建复合终点):直接组65例(13%) vs 分期组53例(11%),HR 1.24(95%CI 0.86-1.79),非劣效P=0.24,未显示非劣效。
- 住院期间心源性休克:直接组18/498例(4%) vs 分期组9/496例(2%)。
- 卒中、大出血、造影剂肾病发生率两组无显著差异。
证据类型、等级与局限
- 证据类型:多中心、开放标签、非劣效、随机对照试验。
- 主要终点分析基于意向治疗人群。
- 参与者和研究者知晓治疗分配,独立临床委员会成员对主要和次要终点评估设盲。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于STEMI合并多支病变且已对罪犯病变行PCI的患者,直接完全血运重建未显示非劣于分期完全血运重建,作者认为该发现可能为未来临床指南关于直接完全血运重建的作用和最佳使用提供参考。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The optimal timing of complete revascularisation for patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease remains unclear. We aimed to assess whether immediate complete revascularisation was non-inferior to staged complete revascularisation during the index admission.
METHODS: We conducted an open-label, randomised, non-inferiority trial at 14 hospitals in South Korea. Patients aged 19 years or older with STEMI and multivessel disease who had undergone percutaneous coronary intervention (PCI) for a culprit lesion were randomly assigned 1:1 to immediate complete revascularisation (PCI for non-culprit lesions during the index procedure) or staged complete revascularisation (non-culprit PCI on another day during the index admission). Web-based, permuted-block randomisation (using mixed block sizes of two or four) was implemented at each participating centre to allocate patients. Non-culprit lesions with 50-69% stenosis were evaluated by fractional flow reserve. Study participants and study investigators were aware of treatment allocation, but members of the independent clinical committee reviewing primary and secondary endpoints were masked to treatment allocation. The primary endpoint was a composite of death from any cause, non-fatal myocardial infarction, or any unplanned revascularisation at 1 year in the intention-to-treat population, and the non-inferiority margin was set at a hazard ratio (HR) of 1·42; if the upper boundary of the one-sided 97·5% CI of the HR was less than 1·42, immediate complete revascularisation would be considered non-inferior to staged complete revascularisation. Reported adverse events consisted of procedural complications, other complications during admission, and in-hospital clinical events occurring during the index admission. This trial is registered with the Clinical Research Information Service (KCT0004457) and ClinicalTrials.gov (NCT04626882). Long-term follow-up is ongoing.
FINDINGS: Between Dec 30, 2019, and Jan 15, 2024, 994 patients were enrolled and randomly assigned to immediate revascularisation (n=498; immediate group) or staged revascularisation (n=496; staged group). The primary endpoint occurred at 1 year in 65 patients (13%) in the immediate group and 53 patients (11%) in the staged group (HR 1·24 [95% CI 0·86-1·79]; pnon-inferiority=0·24). Rates of stroke, major bleeding, and contrast-induced nephropathy did not differ significantly between the two groups. Cardiogenic shock during the index hospitalisation occurred in 18 (4%) of 498 patients in the immediate group and nine (2%) of 496 patients in the staged complete revascularisation group.
INTERPRETATION: Among patients with STEMI and multivessel disease, immediate complete revascularisation was not shown to be non-inferior to staged complete revascularisation during the index admission in terms of incidence of a composite of death from any cause, non-fatal myocardial infarction, or any unplanned revascularisation at 1 year. This finding might inform future clinical guidelines on the role and optimal use of immediate complete revascularisation during the index admission.
FUNDING: Boston Scientific.
参考来源
- Kim MC, Ahn JH, Hyun DY, et al. Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION-STEMI): a multicentre, non-inferiority, open-label, randomised trial. Lancet. 2025. PMID: 40902612. doi:10.1016/S0140-6736(25)01529-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。